Updated Jan. 7, 2016 at 7:48 a.m.

Premium Lock FDA fast tracks Durham startup's prostate cancer drug

Published: 2016-01-07 06:46:00
Updated: 2016-01-07 07:48:01

Cancer research  Cancer research

Less than a year after Durham drug developer Innocrin Pharmaceuticals closed on $28 million in Series D financing to fund testing of its lead cancer therapies, the company has landed a development boost from the U.S. Food and Drug Administration....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders